Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an electrolyte supplement essential for nerve impulse transmission, muscle contraction, and maintaining acid-base balance. It is available in various oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. * Potassium supplementation in patients receiving diuretics or other medications that deplete potassium. ## Adult Dosing Dosing is highly individualized based on serum potassium levels and clinical status. * **Oral:** * **Prevention of hypokalemia:** Typically 20 mEq (1.5 g KCl) once or twice daily. * **Treatment of hypokalemia:** 40-100 mEq (3-7.5 g KCl) per day, divided into 2-5 doses. Maximum daily dose is typically 200 mEq (15 g KCl), but this should be guided by serum potassium and renal function. Extended-release formulations are common. * **Intravenous (IV):** * **Mild hypokalemia (serum K 3.0-3.4 mEq/L):** 10-20 mEq (0.75-1.5 g KCl) added to a large volume IV fluid (e.g., 1000 mL), infused over several hours. * **Moderate hypokalemia (serum K 2.5-2.9 mEq/L):** 20-40 mEq (1.5-3 g KCl) added to a large volume IV fluid, infused over several hours. * **Severe hypokalemia (serum K < 2.5 mEq/L):** Dosing and infusion rate are critical and often guided by local protocol or physician orders. Typically administered via a central line at a rate not exceeding 10-20 mEq/hour (up to 40 mEq/hour in life-threatening situations, with continuous cardiac monitoring). Maximum doses per dose are often limited to 40 mEq (3 g KCl), and daily maximums can reach 200 mEq (15 g KCl), but close monitoring is essential. * **Concentration:** IV KCl should generally not exceed 40 mEq/L (3 g/L) in peripheral lines due to phlebitis risk, and typically not exceed 80 mEq/L (6 g/L) in central lines. ## Pediatric Dosing Dosing is based on age, weight, and serum potassium levels. * **Oral:** * **Prevention:** 1-2 mEq/kg/day (0.075-0.15 g KCl/kg/day), not to exceed 100 mEq/day (7.5 g/day). * **Treatment:** 2-5 mEq/kg/day (0.15-0.375 g KCl/kg/day), divided into doses, not to exceed 200 mEq/day (15 g/day). * **Intravenous (IV):** * Dosing and infusion rates are highly individualized and depend on serum potassium, cardiac status, and renal function. Often follows similar principles to adult IV dosing, with careful attention to infusion rates and concentrations. Local pediatric protocols should be consulted. ## Dose Adjustments * **Renal Impairment:** Dose reduction is necessary. Potassium levels must be closely monitored as impaired renal function can lead to hyperkalemia. * **Adrenal Insufficiency:** Patients may require lower doses due to impaired potassium excretion. ## Contraindications * Hyperkalemia. * Conditions that predispose to hyperkalemia, such as untreated Addison's disease, severe renal impairment, and certain crush injuries or burns. * Known hypersensitivity to potassium chloride. * Esophageal obstruction or delayed gastric emptying (for extended-release oral formulations). ## Adverse Effects * **Gastrointestinal:** Nausea, vomiting, diarrhea, abdominal pain, gastric irritation, ulceration, bleeding, and perforation (especially with oral formulations, particularly sustained-release). * **Cardiovascular:** Arrhythmias, bradycardia, hypotension, cardiac arrest (especially with rapid IV infusion or hyperkalemia). * **Neuromuscular:** Paresthesias, muscle weakness, flaccid paralysis. * **Hyperkalemia:** Fatigue, muscle weakness, paresthesias, confusion, arrhythmias, cardiac arrest. ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene), ACE inhibitors, ARBs, NSAIDs, cyclosporine, tacrolimus:** Increased risk of hyperkalemia. * **Beta-blockers:** Can mask symptoms of hypokalemia and may increase potassium levels. * **Digoxin:** Hypokalemia enhances digoxin toxicity; hyperkalemia reduces digoxin's efficacy. * **Cholinesterase inhibitors:** May enhance neuromuscular blockade. * **Sodium polystyrene sulfonate:** Can reduce absorption of potassium chloride. ## Monitoring * **Serum electrolytes:** Potassium, sodium, chloride, magnesium, bicarbonate. * **Renal function:** Serum creatinine and BUN. * **Electrocardiogram (ECG):** Especially with IV administration or suspected hyperkalemia. * **Urine output:** Monitor for adequacy of renal function. * **Signs and symptoms of hypokalemia and hyperkalemia.** ## Clinical Pearls * Oral potassium chloride, especially sustained-release formulations, should be taken with food or meals to minimize gastrointestinal upset. * Rapid IV infusion of potassium chloride can be fatal and should be avoided. Always dilute and infuse slowly as prescribed. * Always confirm the concentration and total dose of IV potassium chloride with another healthcare professional before administration. * Patients with severe hypokalemia may also have concurrent hypomagnesemia, which can impair potassium repletion. *** *Disclaimer: This information is intended for healthcare professionals and does not replace a thorough review of the current prescribing information, drug monograph, or institutional protocols. Always verify current dosing, indications, contraindications, and safety information before prescribing or administering any medication.*